Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074837 · ClinicalTrials.gov registry record · Phase 1
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
A Phase 1 study of Alzheimer Disease, sponsored by Neuronascent.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04074837 is a Phase 1 study of Alzheimer Disease that has completed, run by Neuronascent. The registered enrollment target is 56 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04074837, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Neuronascent.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NNI-362
Study Locations (1)
California
- Parexel, International - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04074837
The ClinicalTrials.gov registry entry for NCT04074837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is Neuronascent, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04074837 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04074837 about?
NCT04074837 is a clinical study titled "Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers". The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
What is the current status of trial NCT04074837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-08-01. Estimated completion is 2021-08-15.
What conditions does trial NCT04074837 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04074837?
The interventions under investigation include: Placebo (DRUG), NNI-362 (DRUG).
Who is sponsoring clinical trial NCT04074837?
This trial is sponsored by Neuronascent, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04074837 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.